Introduction
62.5 mg of elemental iron in the form of sodium ferric gluconate i.v. None of the patients was administered There are several known haematopoietic growth fachuman recombinant erythropoietin. tors and cytokines. Among them, erythropoietin is an Prostatic carcinoma was treated with antiandrogen essential hormone for the regulation of red blood cell therapy which consisted of a depot preparation of production. Clinical evidence suggests that androgens leuprolide acetate (7.5 mg every 4 weeks by i.m. injecalso play a role in erythropoiesis. Men and women tion) and 250 mg flutamide t.i.d. Androgen blockade exhibit diÂerences in haemoglobin concentration and was very eÂective; serum testosterone, luteinizing horduring puberty, haemoglobin levels increase only in mone, and prostate-specific antigen levels decreased in males. Moreover, it has been shown that haemoglobin all patients and reached undetectable levels after the levels decline after castration or antitestosterone 3rd month of antiandrogen treatment. therapy [1] [2] [3] . Levels of erythropoietin are similar in Figure 1 shows the haemoglobin levels 6 months both men and women, and therefore it is assumed that before, and after the initiation of antiandrogen treattestosterone is responsible for the observed diÂerences ment. Haemoglobin levels were decreased 1 month in haemoglobin levels.
post-treatment and the three patients required Anaemia in uraemic patients is a consequence recombinant human erythropoietin therapy to control of inappropriately low erythropoietin production.
anaemia at 3, 4 and 5 months respectively postGenerally, it is most severe in women and children, antiandrogen treatment. The patients remained suggesting that erythropoiesis in end-stage renal failure is also influenced by androgens [4] . A role for androgens in erythropoiesis is supported by the fact that level. The combination of these two substances results in total androgen blockade [7 ] . We observed a sharp decline in the haemoglobin levels of the three male haemodialysis patients with prostatic carcinoma who were treated with these two drugs. A mild, but statistically significant decrease in haemoglobin was also observed in male patients with normal renal function treated with a similar androgen blockade regimen [3 ] .
Before antiandrogen therapy, the haemoglobin levels of all three patients with hypogonadism were maintained with intravenous iron supplementation. One month following testosterone blockade, there was a profound decline in haemoglobin concentration not associated with changes in erythropoietin levels. This fall in haemoglobin concentrations cannot be attributed to malignancy since it coincided with the initiation of antiandrogen therapy and did not improve with the Our data suggest that the low testosterone levels in these patients were necessary to maintain haemoglobin concentrations through a mechanism independent of asymptomatic after 1 year of antiandrogen treatment the erythropoietin level. Therefore, testosterone with a stable haemoglobin concentration. At this time appears to be involved in the regulation of erythrohaemoglobin levels and the maintenance dose of intrapoiesis in male patients with chronic renal failure. The venous recombinant erythropoietin were 9 g/dl and mechanism of action of androgenic steroids may be an 152 IU/kg/week ( patient 1), 10.1 g/dl and 347 increase in the sensitivity of erythroid progenitors to IU/kg/week (patient 2 ) and 9.8 g/dl and 384 erythropoietin. IU/kg/week (patient 3 ) respectively. The serum erythropoietin levels did not change during the first 3
